00:00:00Overview of GPRC5D and its clinical significance
00:02:30Key findings from Phase II TALisman study regarding dysgeusia assessment for patients receiving talquetamab
00:06:25Mitigating dysgeusia and dry mouth arising from GPRC5D-directed therapy
00:11:49Key findings from the Phase III MonumenTAL-3 study
00:15:16Selection factors for GPRC5D- and BCMA-directed therapies
00:18:30Managing extramedullary multiple myeloma (MM) with GPRC5D-targeted therapies and beyond
00:20:47Key findings with arlocabtagene autoleucel (arlo-cel) for relapsed/refractory (R/R) MM
00:25:32Ramantamig and other GPRC5D-targeted approaches
00:28:42Comparing arlo-cel to ciltacabtagene autoleucel for MM; CNS issues with GPRC5D-directed therapies
00:38:27Case: A man in his late 70s with a history of chronic obstructive pulmonary disease and t(4;14) R/R MM who receives fourth-line talquetamab and attains a very good partial response
00:45:18Cases: A man in his late 40s with t(11;14), del(17p) R/R MM who enrolls in the Phase II QUINTESSENTIAL-2 study for third-line treatment; a man in his late 60s with t(11;14), del(17p) MM and early relapse after third-line autologous stem cell transplant
00:47:35Guidance on sequencing BCMA- and GPRC5D-directed therapies
00:52:27Importance of tumor debulking; access to arlo-cel